News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Kiran Naqvi, MD

Articles by Kiran Naqvi, MD

Clinical Scenario: A 70-year-old female with LR-MDS

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

January 30th 2026

Experts discuss treatment options for a 70-year-old woman with low-risk MDS, emphasizing the need for more clinical trial data and real-world evidence.

Clinical Scenario: A 77-year-old male with newly diagnosed LR-MDS

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

January 23rd 2026

Clinical Scenario A: 77-year-old male with newly diagnosed LR-MDS

Debate Topic 3: Benefits of Completing Lupatercept

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

January 23rd 2026

Experts debate the optimal dose escalation strategy for Luspatercept in treating low-risk MDS, emphasizing patient-centric approaches and long-term outcomes.

Debate Topic 2: Defining 1L therapy

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

January 16th 2026

Experts debate the efficacy of luspatercept versus erythropoietin in treating low-risk MDS, emphasizing individualized patient care and emerging therapies.

Debate Topic 1: Treatment initiation

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

January 16th 2026

Experts debate the optimal timing for initiating treatment in low-risk MDS, emphasizing early intervention to enhance patient quality of life.

IMERGE Trial – ASH 2025 Updates

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

January 9th 2026

Explore the promising long-term outcomes of the IMERG trial, highlighting Emtresat's efficacy and safety for lower-risk MDS patients.

RWO Hb Assessment in 1L

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

January 9th 2026

Explore real-world outcomes of hemoglobin treatment in low-risk MDS patients, comparing luspatercept and ESA therapies in a recent study.

Insights into RWO 1L lupatercept vs 2L ESA

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

January 2nd 2026

Explore real-world outcomes of Luspatercept and second-line ESAs in treating low-risk MDS, revealing promising response rates and treatment insights.

RWO 1L lupatercept vs 2L ESA

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

January 2nd 2026

Encountering an error while trying to access content? Discover solutions to troubleshoot and resolve connectivity issues effectively.

Clinical Implications of COMMANDS Trial

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

December 19th 2025

FACE-OFF: Low-Risk MDS ASH 2025

Introduction and Phase 3 COMMANDS Trial

BySaulius Girnius, MD,Jamie Koprivnikar, MD,Aditi Shastri, MBBS,Brittany Ragon, MD,Jamile Shammo, MD, FASCP, FACP,Michael Haddadin, MBBS,Kiran Naqvi, MD

December 19th 2025

FACE-OFF: Low-Risk MDS ASH 2025

Latest Updated Articles

Introduction and Phase 3 COMMANDS Trial
Published: December 19th 2025 | Updated:

Trending on CancerNetwork

Exploring The Application of Artificial Intelligence in Radiology Scans

Indirect Comparison Supports Zanubrutinib Monotherapy in CLL/SLL Care

Adjuvant Chemo Noninferor at 3 Months Vs 6 Months in Stage II/III CRC

Navigating the Surgical Nuances of Inflammatory Breast Cancer and Phyllodes Tumors

Multimodal Regimen Yields Remission in Liver Metastases from Uveal Melanoma